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Summary The Wnts can be classified into two classes based on their ability to transform cells. The Wnt5a class can antagonize the effects
of transforming Wnts partly through effects on cell migration. To understand the mechanisms of regulation of Wnt5a, we investigated its
expression in human normal and breast cancer cell lines. Elevation of Wnt5a in HB2, a normal breast epithelial cell line, was linearly
correlated with cell density, but this did not occur in cancer cell lines. We examined intracellular events responsible forthe regulation of Wnt5a
by cell to cell contacts, using various metabolic agents known to affect signal transduction pathways. Agents that selectively blocked protein
kinase C (calphostin C) or protein tyrosine kinases (genistein) reduced the level of Wnt5a expression markedly. Protein kinase C activation by
phorbol 12-myristate 13-acetate up-regulated Wnt5a partly through prolongation of Wnt5a mRNA half-life. Cytoskeleton reorganization
following cytochalasin D treatment caused an induction of Wnt5a, which was associated with changes in cell morphology. Calphostin C did
not block these effects, showing that protein kinase C is acting upstream of cytoskeletal modulation. However, the cancer cell lines treated
with cytochalasin D showed no changes in cell morphology or Wnt5a induction, suggesting disruption of this regulatory pathway in cancer.
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Morphogenesis in multicellular organisms requires a variety ofcell
to cell signals, among which local cell-cell signalling events are of
particular importance. Wnt proteins are secreted proteins and are
known to be such local signalling factors (Nusse and Varmus,
1992). The extracellular Wnt signal is transmitted and sensed by
other cells in an auto- or paracrine way. The coordination of Wnt
signals with other internal signals to induce the appropriate changes
in other gene activities is poorly understood. The diversity offunc-
tion between these genes, when overexpressed in Xenopus
embryos, allows them to be divided into two distinct classes; the
Wnt1 class, which includes Wntl, 3a, 8 and 8b and which promotes
axis duplication; and the Wnt5a class, which includes Wnt5a, 4 and
11, which alter morphogenetic movements. The members of the
Wnt5a class are thought to antagonize the mitogenic stimulatory
effect of the Wnt class by decreasing calcium-dependent cell
adhesion by an unknown mechanism (Torres et al, 1996).
The signalling pathway used by Wnt5a class is poorly under-
stood. InXenojpus embryos, ectopic expression ofWnt5a alters the
morphogenetic movement by blocking the normal elongation of
blastula cap explants induced by activin, suggesting a function for
Wnt5a in blocking cell motility (Moon et al, 1993). This function
is not yet understood in mammalian cells, but down-regulation of
Wnt5a by hepatocyte growth factor (HGF), followed by cell
branching in collagen (Huguet et al, 1995) and the sequence
homology between human and Xenopus Wnt5a (90% at amino
acid level), supports a similar role for human Wnt5a in controlling
cell movement. In previous studies we have shown that Wnt5a is
Received 24 July 1997
Revised 4 February 1998
Accepted 5 February 1998
Correspondence to: M Jonsson, Division of Experimental Pathology, Lund
University, University Hospital MAS, Entrance 78, SE-205 02 Malmo,
Sweden
up-regulated in benign and malignant breast tumours, ten- and
fourfold respectively, compared with normal breast tissue
(Lejeune et al, 1995). Moreover, it has also been documented that
Wnt5a is up-regulated in several other cancer types, such as lung,
prostate cancer and malignant melanoma (lozzo et al, 1995), as
well as in colon cancer (Vider et al, 1996). The mechanisms
involved in up-regulation of Wnt5a in cancer have not been eluci-
dated so far, but as several Wnts, including Wnt5a, are widely
expressed in both embryos and adult tissue they may, therefore,
have a role in maintenance of adult tissue organization.
To study the cellular response to Wnt5a signal and the mecha-
nisms involved in the regulation ofWnt5a, the HB2 cell line has been
shown to be a suitable cell model. We have previously shown that
Wnt5a is regulated by confluence, cell shape transition and HGF in
this cell line (Huguet et al, 1995). In this study, we have investigated
the signalling pathways involved in the regulation ofWnt5a expres-
sion in cell density and cell to cell contact. We have found that Wnt5a
expression was regulated by increasing cell density in HB2 cells,
with a peak at late confluence. This may provide an additional mech-
anism through which Wnt5a inhibits cell motility beyondcell conflu-
ence. We have also shown that protein kinase C (PKC), tyrosine
kinase activities and cytoskeleton rearrangement are involved in the
regulation ofWnt5a at cell confluence. The pathways by which PKC
regulates the Wnt5a message level may thus be relevant to Wnt5a
up-regulation in cancer, as well as in normal development, providing
a link between regulatory pathways of kinases involved in many
processes in adult tissues, including carcinogenesis and the pathways
ofembryonic differentiation.
MATERIALS AND METHODS
Cell culture
Mycoplasma-free HB2 cells [a subclone of the MTSVI-7 line
(Bartek et al, 1991)] obtained from Dr Joyce Taylor-Papadimitriou
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(Imperial Cancer Research Fund, Lincoln's Inn Fields, UK) were
cultured as described previously (Huguet et al, 1995). Briefly, cells
were seeded at different densities into a 10-cm Beckton-Dickinson
tissue culture plate in Dulbecco's modified Eagle medium
(DMEM) (Clare Hall Laboratories, Imperial Cancer Research
Fund, UK) supplemented with 10% fetal calf serum (FCS),
10 g ml bovine insulin and 5 jg ml-' hydrocortisone in 95% air,
5% carbon dioxide, at 37°C. Foranalysis ofcell density-dependent
expression of Wnt5a, HB2 cells were plated at different densities.
Cells were harvested when they reached a cell density between
early subconfluence (150 cells mm-2 < 5% confluence) and late
confluence (1500 cells mm-2 2 95% confluence). Breast cancer
cell lines MCF-7, T-47D, MDA-MB-361 and BT-474 (from the
American Type Culture Collection) were cultured in DMEM
supplemented with 10% FCS and incubated at the same conditions
as described for HB2 cells. All laboratory reagents were from
Sigma unless otherwise specified.
Preparation of RNA from subconfluent cells cultured in
various conditions
To investigate whether the differences in Wnt5a expression
between cells growing in different states depended upon soluble
factors, subconfluent cultures were grown in conditioned medium
from confluent cell cultures for 24 h and Wnt5a expression was
compared with cells grown normally. The expression of Wnt5a in
cells growing to subconfluence on a matrix extracted from
confluent HB2 cells by repeatedly freezing and thawing the
cells was also examined. To exclude the effect of supplements
on Wnt5a expression, HB2 cells were grown in medium with
and without each supplement. Total RNA was prepared from
these cultures and analysed by ribonuclease (RNase) protection
assays.
RNase protection assay
Antisense [R-32P]CTP (Amersham) transcripts of Wnt5a were
generated from a 384-basepair fragment of the gene cloned in the
plasmid bluescript KS+ (Stratagene). Antisense transcripts were
generated from the construct using T7 RNA polymerase after
linearization with EcoRV. For the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) probe, which was used as internal
control, a 120-basepair fragment ofthe GAPDH was cloned in the
plasmid bluescript KS+ to generate antisense GAPDH transcripts
as described previously (Huguet et al, 1995). RNase protection
assays were performed on 10 jg of total RNA as described
previously. The RNA was analysed on a 1% agarose gel to check
purity and quantified by spectrophotometry at 260 nm. Total RNA
was hybridized overnight at 55°C with labelled antisense probes.
Exposing cells to different drugs may modulate GAPDH expres-
sion, thereby questioning the validity of GAPDH as loading
control. To circumvent this problem, we spiked all samples with 1
jig of total RNA from K562 cells (which strongly overexpress x-
1-globin) and included a [a-32P]CTP labelled antisense cx-globin
mRNA to the hybridization solutions. This hybridizes to the a-
globin mRNA in the spike (Frith and Ratcliffe, 1992), thereby
providing an external loading control.
Image analysis
Autoradiographs of RNase protection assay were scanned using a
phosphoimager to quantify the intensity of Wnt5a, GAPDH and
globin spike signals. Wnt5a mRNA value for each sample was
normalized to GAPDH and to globin mRNA spike. The mean
values of Wnt5a signal intensities were compared with that of
matched controls in each assay and are represented as a percentage
of the value for Wnt5a mRNA in control samples. All values
represent a minimum of three different measurements in at least
three independent experiments.
Measuring half-life of Wnt5a mRNA
Wnt5a mRNA half-life was measured using actinomycin D (Act
D). Act D was solubilized in dimethylsulphoxide (DMSO) as a
stock solution of 10 mg ml and used at a final concentration of 10
jig ml-'. The drug was added to confluent HB2 cultures and incu-
bated in duplicate plates with matching controls. Wnt5a mRNA
was then analysed at 0.5-4 h after addition of Act D. To investi-
gate the effect of activation of PKC on Wnt5a mRNA half-life,
confluent cells were preincubated in the presence and absence of
3 nM phorbol 12-myristate 13-acetate (PMA) for 45 min followed
by washing three times with phosphate-buffered saline (PBS). Act
D (10 jg ml-') was subsequently added and the cells were incu-
bated for 2-4 h.
Use of metabolic agents
The metabolic agents used in this study as modulators of intracel-
lular signalling events are listed in Table 1. In all assays, HB2 cells
were grown to confluence to obtain the maximum induction of
Wnt5a. Drugs were then applied to the culture and their possible
effect on Wnt5a expression was analysed after 4-6 h incubation (a
Table 1 List of metabolic agents used in the present study
Metabolic agent Effect Solvent/stock (mM) Concentrations Average concentrations
studied used in the other
studies
H7 Inhibits serine threonine kinases DMSO/100 1-150gM 1-150gM
Herbimycin A Inhibits tyrosine kinases DMSO/1 1-3gM 0.1-15gM
Okadaic acid Inhibits serine threonine kinases Acetone/0.1 0.1-100 nM 0.1-150 nM
Cytochalasin D Inhibits actin polymerization DMSO/10 1-3gM 0.2-10 JM
Calphostin C Inhibits PKC DMSO/100 0.1-1 nm 0.1-10 nM
Genistein Inhibits tyrosine kinases DMSO/100 50-150gM 20-150gM
PMA Stimulates PKC DMSO/10 1-20 nM 1-100 nM
Sodium vanadate Inhibits tyrosine phosphatase H20/0.1 1-150gM 1-200gM
H89 Inhibits PKA DMSO/100 50-100gM 10-150gM
Actinomycin D Inhibits RNA synthesis DMSO/10 10 lM 5-15gM
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time generally sufficient to obtain the full effect of the drugs).
Dose-response studies were carried out to optimize concentrations
and solvent controls were used in test plates. Agents were prepared
as stocks in minimum volumes of solvents, e.g. in DMSO or
acetone, to reduce the solvent concentration in assays below 0.1%
(v/v). Cell viability was assessed by cell morphology using an
inverted microscope or by trypan blue exclusion. All agents were
generally used at a concentration ranging from lx to lOOx the inhi-
bition constants (K*), or at concentrations causing 50% inhibition
(IC50) measured in vitro. Throughout the experiments cells were
incubated in serum- and supplement-free medium, which was
changed 3 h before drug addition.
Western blot analyses
Cells from confluent or subconfluent HB2 cultures were washed
and sonicated in ice-cold buffer A [50 mm Tris-HCI (pH 7.4,
20°C), 150 mm sodium chloride, 2 mm EDTA, 1 mM EGTA, 1 mM
sodium orthovanadate, 50 mm sodium fluoride, 1 mm sodium
pyrophosphate, 2 mm PMSF, 1 jig ml-' aprotinin, 1 jg ml-1
leupeptin and 0.1% SDS]. All steps were carried out on ice or at
4°C. Protein concentration was determined by the method of
Bradford using BSA as a standard (Bradford, 1976). A 50-jig
aliquot of total protein from each sample was separated by 8%
SDS-polyacrylamide gel electrophoresis under reducing condi-
tions. The proteins were transferred electrophoretically onto a
polyvinylidene fluoride membrane (Immobilon P, Milipore). The
membrane was then probed with the anti-PKC monoclonal anti-
body, MC5 (Young et al, 1988). The antigen-antibody complex
was detected using peroxidase-conjugated rabbit anti-mouse IgG,
followed by use of an enhanced chemiluminescence (ECL) detec-
tion system (Amersham). Mouse brain extract was used as positive
control.
To study the effect ofE-cadherin extracellular domain blocking
on Wnt5a expression, confluent cells were incubated with 50 mg
ml-' HECD-1, mouse anti E-cadherin monoclonal antibody
(Shimoyama et al, 1989) or isotype-matched control mouse IgG
for 16 h. Total RNA was extracted from cells and used for RNase
protection assay. The level of E-cadherin protein in confluent and
subconfluent HB2 cells was measured using immunoblotting as
described above.
RESULTS
Effect of cell density on the expression of Wnt5a in HB2
cells
To' demonstrate cell density-dependent expression of Wnt5a,
single-cell suspensions were plated at a range of different cell
densities. Cells were harvested and counted when the plate with
the highest cell number reached confluence. Results from RNase
protection assays showed a linear correlation between increased
cell density and Wnt5a message level, i.e. lowest expression at
early subconfluence compared with the highest message level in
confluent cells (Figure 1). To clarify whether the elevation of
Wnt5a by cell density was due to a gradual accumulation ofstimu-
latory or inhibitory factors in conditioned medium, HB2 cells were
grown to subconfluence in conditioned medium from confluent
cells. However, Wnt5a expression in this subconfluent culture was
similar to that of matched controls. As Wnt5a is secreted from
cells to the extracellular matrix, we next examined whether
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Figure 1 Regulation of Wnt5a expression by cell density. (A) RNase
protection assay showing Wnt5a and corresponding GAPDH signals in HB2
cells grown to different densities. Cells were harvested by scraping cells from
the plates at various cell densities with the lowest density corresponding to
150 cells mm-2 and highest density at 1500 cells mm-2. Ten ,ug of total RNA
was used for each sample in RNAase protection assay. Wnt5a mRNA levels
present densitometer units adjusted according to GAPDH mRNA levels. (B)
Phosphoimage analysis of the data showing a linear correlation between up-
regulation of Wnt5a and increased cell density (s.d. ± n = 3)
growing subconfluent cells on a confluent cell matrix could
increase the level ofWnt5a expression. We found that cells grown
on a matrix prepared from confluent HB2 cells had a similar level
of expression to that of controls (data not shown). Thus, these
results indicate that expression ofWnt5a is independent of soluble
factors or other proteins present on the extracellular matrix, but is
regulated by gradually increased cell to cell contacts.
Half-life of Wnt5a mRNA
In order to investigate the mechanism ofaction of signal transduc-
tion processes on the regulation of Wnt5a expression in confluent
HB2 cultures, we measured the half-life of the Wnt5a mRNA in
confluent cells by blocking new mRNA synthesis with Act D. The
mean half-life of Wnt5a transcripts in confluent HB2 cells was
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Figure 2 Preincubation of cells with PMA prolongs the half-life of Wnt5a mRNA (A) Wnt5a and corresponding GAPDH signals in confluent HB2 cells
incubated in the presence or absence of Act D to determine Wnt5a mRNA half-life. (B) RNase protection assay showing Wnt5a and GAPDH signals in confluent
HB2 cells preincubated in the presence (+) or absence (-) of 3 nm PMA for 45 min. Cells were washed three times with PBS and then continuously incubated
with Act D (10 jg ml-1) for indicated time intervals. (C) Phosphoimage analysis of the data obtained from incubation of cells with Act D or matching controls
(D, s.d. ± rn=3), or from preincubation of cells with PMA before adding Act D with matching controls. Wnt5a half-life is prolonged greater than 1.5 times in cells
stimulated with PMA (0, s.d. + n = 3). Wnt5a mRNA levels present densitometer units of each sample as a percentage of the matching control mRNA adjusted
according to GAPDH mRNA levels
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Figure 3 Treatment of breast cancer cells by PMA and cytochalasin D has no effect on expression of Wnt5a. RNase protection assay showing Wnt5a and
GAPDH signals in confluent breast cancer cells treated with 3 nm PMA for 45 min and 1.5gM cytochalain D for 6 h. Treatment of confluent HB2 cells with the
indicated concentration of PMA and CD induced the highest expression level of Wnt5a in confluent HB2 cells (see Figures 5 and 7). Lane 1 showing expression
of Wnt5a in untreated HB2 which was used as a positive control for the assay. The '0' indicates expression of Wnt5a in breast cancer cell lines at 0 time
estimated as 140 ± 5 min (Figure 2A). Comparison ofthe GAPDH
signal between samples exposed to the optimized concentration of
drugs and that of controls showed no significant change in
GAPDH expression, proving GAPDH to be a reliable internal
control.
Regulation of Wnt5a gene transcription by PMA
Two motifs, TATT and ATTA, repeated 32 and ten times respec-
tively, are identified at the 3' untranslated region (UTR) of the
Wnt5a sequence, implying a possible rapid degradation of Wnt5a
mRNA (Clark et al, 1993). As a phorbol ester-responsive element,
AP-1, is present in the Wnt5a promoter region (Danielson et al,
1995), alteration of this pathway by PKC activation could be one
possible mechanism ofregulation on contact. To examine whether
Wnt5a mRNAs half-life was affected by treatment of cells with
PMA, cells were preincubated with 3 nM PMA to modulate PKC
activity prior to adding Act D. The results show that the half-life of
Wnt5a was prolonged greater than 1.5 times (tU1, = 230 ± 6 min,
Figure 2B) in response to PMA. This prolongation could reflect a
corresponding increase in mRNA at the transcriptional level or
stabilization of Wnt5a message by PMA, as has been reported for
other labile mRNA (Ohh et al, 1994).
Involvement of PKC in the regulation of Wnt5a
To gain insight into the intracellular mechanisms involved in
confluence-induced accumulation of Wnt5a, several drugs with
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Figure 4 Effect of protein kinase C inhibitors on expression of Wnt5a. (A) Confluent HB2 cultures were incubated with H7 at indicated concentrations. Wnt5a
expression were then analysed by performing RNase protection assays and loading 10 .g total RNA per lane. (B) Phosphoimage analysis of the data showing
the effect of H7 on Wnt5a expression (s.d. + n = 4). (C) shows the Wnt5a and corresponding GAPDH signals from cells incubated with calphostin C for 6 h at
indicated concentrations. (D) Phosphoimage analysis of data showing that calphostin C down-regulates Wnt5a expression in a dose-dependent manner (s.d. +
n = 4). Values represent the densitometric units for each sample as a percentage of the matching control mRNA adjusted according to GAPDH mRNA levels
different specificities for tyrosine and serine/threonine kinases
were tested in this study. Calphostin C, which interacts with the
regulatory domain of PKC and inhibits its activity (Kobayashi et
al, 1989), and 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine
(H7), a competitive PKC inhibitor with respect to ATP, and which
inhibits the active centre of PKC (Hidaka et al, 1984), were tested.
Calphostin C and H-7 both reduced the Wnt5a message level in a
dose-dependent manner (Figure 4), implicating PKC phosphoryla-
tions as an important step in the confluence-induced expression.
PMA is known to have a biphasic effect on stimulation of PKC,
i.e. at low concentrations it acutely stimulates PKC by mimicking
diacylglycerol activity and at high concentrations it down-regu-
lates PKC activity by depleting intracellular PKC (Nishizuka,
1986). To demonstrate further the involvement of PKC activity in
this regulation, we tested different doses ofPMA to modulate PKC
activity. Exposure of cells to 3 nm resulted in an up-regulation of
Wnt5a, whereas treatment with PMA at a concentration 5 nM
reduced expression (Figure 5), reflecting involvement of PKC
activity in this regulation. As the protein kinase A (PKA)
signalling pathway is involved in Wingless (Drosophila homo-
logue ofWnt1) regulation (Li et al, 1995), we next investigated the
ability of N-[2-(p-bromocinnamyl-amino)ethyl]-5-isoquinoline-
sulphonamide (H89), a potent inhibitor of protein kinase A
(Nishizuka, 1986), to modulate Wnt5a expression. However, H89
had no effect on the expression of the Wnt5a, suggesting a class-
specific regulation between different Wnts (data not shown).
Effect of phosphatase inhibitors on Wnt5a expression
The entry of cells into stationary growth phase following growth
inhibition is associated with reduced tyrosine phosphorylation in
growth factor-induced mitogenic signalling pathways. This has led
to the proposal that the activity of phosphatases may be involved
in contact inhibition (Brady-Kalnay and Tonks, 1995). To assess
the impact of phosphatase activity in the regulation of Wnt5a,
confluent HB2 cells were exposed to okadaic acid, a serine/threo-
nine phosphatase inhibitor (Cohen et al, 1990), and to sodium
orthovandate, a protein-tyrosine phosphatase inhibitor. Incubation
of confluent HB2 cells with okadaic acid at 10 nm for 6 h resulted
in no significant changes in Wnt5a message level. Exposure of
cells to vanadate also had no effect but was associated with a
refractile cell morphology (Klarlund, 1985) (data not shown).
Effect of protein tyrosine kinase inhibitors on the
Wnt5a expression
To investigate the role of the protein-tyrosine kinases (PTKs)
phosphorylation cascade in the signalling pathway leading to high
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Figure 5 Effect of PMA is time and concentration dependent. (A) RNase protection assay showing Wnt5a and GAPDH signals in confluent HB2 cells treated
with 3-5 nm of PMA for 45 min. (B) RNase protection assay shows that the 8 h incubation with 10-20 nM PMA inhibits Wnt5a expression. (C) Phosphoimage
analysis of data obtained from exposure of cells to PMA for 45 min (A) (s.d. ± n = 3) or for 8 h (B) (s.d. ± n = 3). Values represent the densitometric units for
each sample as a percentage of the matching control mRNA adjusted according to GAPDH mRNA levels
Wnt5a expression at confluence, HB2 cells were treated with the
PTK inhibitors genistein and herbimycin A. Genistein is an
isoflavone compound that inhibits the ATP binding sites of these
enzymes (Itoh et al, 1987), while herbimycin A blocks tyrosine
kinases by affecting a refolding pathway involving hsp90 (Gradin
et al, 1994). Genistein strongly suppressed the expression of
Wnt5a in a dose-dependent manner. Exposure of cells to 100 gM
genistein for 4 h reduced the message level to 30% of that of
controls (Figure 6A and B) while the effect of herbimycin A was
less pronounced than genistein, i.e. at 3 gM for 4 h it reduced the
Wnt5a message level to 60% ofthat ofthe controls (Figure 6C and
D). Tyrosine phosphorylation pathways involving direct phos-
phorylation, rather than the herbimycin A-regulated degradation
pathway, may therefore be important in Wnt5a regulation.
Involvement of cytoskeletal reorganization in the
regulation of Wnt5a
Because the effects on Wnt5a up-regulation at confluence may be
mediated via the cytoskeleton, we examined the effect of cytocha-
lasin D (CD) on Wnt5a expression. The results ofRNase protection
assays showed that CD elevated the Wnt5a message level greater
than 1.5 times compared with that of the controls (Figure 7).
Moreover, we observed that a cell morphology change (from flat to
round form) occurred after exposure to CD, which is consistent
with the function of CD as a cell shape modulator. Cell viability
and GAPDH expression were unchanged compared with that of
matching controls. To determine whether the action ofCD-induced
up-regulation was via PKC, we incubated cells with 1.5 gM CD
plus 0.5 gM calphostin C for 6 h. The results showed that PKC inhi-
bition did not affect the induction of Wnt5a by CD. It provides
evidence that microfilament rearrangement is a second mechanism
involved in regulation of Wnt5a expression at confluence.
Expression of Wnt5a in breast cancer cell lines
Although Wnt5a is upregulated in a subset of breast tumours,
expression of Wnt5a is barely detectable in many breast cancer
cell lines. Increased PKC activity has been reported in breast carci-
nomas suggesting a role for PKC in breast malignancy (Ways et al,
1995). We examined whether PKC activation could induce the
Wnt5a message in breast cancer cell lines. However, incubation
with PMA at a concentration sufficient to induce Wnt5a expres-
sion in HB2 cells produced no effect on the Wnt5a expression in
cancer cells. Moreover, the response to cytoskeleton reorganisa-
tion by CD under the same conditions as for HB2 cells had no
effect on Wnt5a expression in these cell lines. Even though CD is
frequently used as a convenient cell shape modulator, it could not
change the cell morphology of breast cancer cells in contrast to
HB2 cells indicating a disruption of the Wnt5a regulatory path-
ways in breast cancer (Figure 3).
Blocking E-cadherin action and PKC immunoblotting
Accumulation of E-cadherin in cells at confluence has been
reported (Takahashi and Suzuki, 1996). To determine whether
E-cadherin-mediated cell-cell adhesion has a role in regulation of
Wnt5a expression, confluent HB2 cells were incubated with a
blocking antibody for E-cadherin. Results from RNase protection
assay showed no differences in Wnt5a expression between cells
incubated with E-cadherin antibody and matching controls.
Western blot analysis of immunoreactive E-cadherin in HB2 cells
showed that an equal amount of E-cadherin was present in cells at
different growth states. We also tested the possibility that the PKC
protein level might be elevated in a confluent-dependent manner
in contact-inhibited cells compared with the proliferating HB2
cells. We found that cells in confluent and subconfluent cultures
had a similar amount of immunoreactive PKC, despite their
growth states (data not shown).
DISCUSSION
Several changes in signalling pathways occur when cells become
confluent, including changes in membrane receptors such as
epithelial growth factor receptor (EGFR), expression of autocrine
or paracrine growth factors and proto-oncogenes, activity of tran-
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Figure 6 Effects of tyrosine kinase inhibitors on regulation of Wnt5a. (A) RNase protection assay showing Wnt5a and corresponding GAPDH signals in
confluent HB2 cells incubated with genistein for 6 h at indicated concentrations. (B) Phosphoimage analysis of data showing a dose-dependent down-regulation
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cells incubated with cytochalasin D for 6 h at indicated concentrations. (B) Phosphoimage analysis of the data showing an up-regulation of Wnt5a expression by
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scription factors, responsiveness to growth factors and changes in
cellular architecture (Bost and Hjelmeland, 1993; Soprano, 1994;
Xie et al, 1994). Similarly, elevation of Wnt5a expression in HB2
cells can be correlated with cell density. Previously, we have
shown that this induction was not related to quiescence or to
growth arrest by serum starvation (Huguet et al, 1995), and in this
study we were able to exclude the possible effect ofstimulatory or
inhibitory soluble factors produced by cells at confluence. We also
excluded the possibility that regulatory factors could bind to and
accumulate on the extracellular matrix, exerting a biological effect
on neighbouring cells and Wnt5a expression. Thus, these data
together imply that Wnt5a expression was dependent on cell to
cell contacts, which were gradually achieved as cells became more
dense rather than confluence itself.
To elucidate the signalling pathways responsible for the regula-
tion of Wnt5a expression, we next analysed the effects of meta-
bolic agents known to affect both intracellular signalling events
and the stability and organization of cell-cell contacts. Wnts
expression is maintained or up-regulated by a paracrine pathway
for the Wnt1 class in lower organisms. The wingless (WG) signal
is via dishevelled and zeste white 3 (the Drosophila homologue of
glycogen synthase kinase) involving hedgehog and patched. The
latter pathway is modified by PKA and WG expression in the
responding cells (Li et al, 1995). Thus, steps in this pathway may
be involved in paracrine regulation of human Wnts during cell
density changes. However, we found that modification of protein
kinase A activity had no effect.
In our study, Wnt5a expression is up-regulated following PKC
activation and down-regulated following its inhibition. The
serine/threonine phosphatase inhibitor okadaic acid showed no
significant effect on Wnt5a expression. It has not previously been
shown in Drosophila or Xenopus embryos that PKC may have a
role in regulating Wnt expression. However, it has been shown
that in vitro glycogen synthase kinase 3 (GSK3, vertebrate homo-
logue ofZW3) phosphorylates AP-I at sites proximal to the DNA-
binding domain ofthis protein, thereby inhibiting AP-1 binding to
its target promoter (Boyle et al, 1991). Recently, it has been
reported that inhibition of GSK3 is required for Wnt5a signalling
as well as for Wntl (He et al, 1997). Several PKC isoforms, for
example oc, P1 and y, phosphorylate GSK3, thereby inhibiting its
activity and providing a possible mechanism for the actions
dishevelled in response to Wnt signalling. Taken together, these
results suggest the possibility that one mechanism of regulation
may involve the prolongation of mRNA half-life at the transcrip-
tion level by stimulating AP-1-mediated transactivation of Wnt5a
in confluent cells through inactivation ofGSK3 kinase by PKC. In
addition to this, the Wnt5a mRNA contains several AUUUA
sequences in its 3' untranslated region, suggesting that phosphory-
lation by PKC could also play a role in the regulation of the
activity ofAU-binding proteins (Gillis and Malter, 1991; Stephens
et al, 1991), leading to stabilization ofWnt5a mRNA.
Stabilization of actin cables can block cell movement and, at
confluence, changes occur in the actin cables, resulting in changes
in cell morphology. Modulation of the assembly of the microfila-
ment system following CD treatment releases the sequestered
nuclear factors and allows translocation to the nucleus and regula-
tion of target genes, e.g. positive regulation of rat p52 (API-I)
(Zambetti et al, 1991; Higgins and Ryan, 1992). We found that
stabilization of actin filaments by CD results in elevation ofWnt5a
expression, similar to the effect produced by PKC activation,
although blockade of E-cadherin did not inhibit signalling. Thus,
cytoskeletal changes represent a second pathway regulating Wnt5a
expression. Breast cancer cell lines differed markedly from the
normal luminal cell line in having very low expression of Wnt5a,
which is not affected in response to PMA orCD. These cells did not
show any short-term morphological response to the latter drug, and
are also known to have abnormalities in function and expression of
the E-cadherin pathway. Thus, in vitro the cancer cell lines do not
show the up-regulation ofWnt5a reported in vivo. It is possible that
the effects in vivo represent the predominance ofthe PKC pathway,
and in vitro growth of cells on flat surfaces does not adequately
represent the appropriate signals to the cytoskeleton to allow
Wnt5a expression. The abnormalities in the cancer cells in response
to CD compared with the HB2 cells nevertheless show that there
are major differences in the pathway in transformed cells.
Tyrosine kinase inhibitors also blocked the effects at conflu-
ence, although it is known that tyrosine phosphatase activity
increases at confluence with growth factor receptors as cellular
targets, thereby antagonizing cellular responsiveness to growth
factors. However, tyrosine kinases such as Src are regulated down-
stream of PKC and there is basal activity of tyrosine kinases
detectable at confluence. Thus, the tyrosine kinase inhibitors may
modulate downstream effects of PKC activity or represent a
parallel pathway.
A shortcoming of the study was that the analyses had to be
carried out on confluent cells, because most of the signalling
inhibitors blocked proliferation and development of cell contacts,
so it was not possible to analyse mechanisms as the cells contacted
each other. Thus, the analyses showed pathways involved in main-
taining expression of Wnt5a after contact inhibition, but these are
not necessarily the same as those that were involved in the initial
up-regulation.
Nevertheless, our results show that Wnt5a expression is regu-
lated by confluence, by a CD-mediated signalling pathway to the
cytoskeleton and by a protein kinase-dependent mechanism
involving tyrosine kinases. Several different pathways involved in
migration and modelling of tissues emerge as Wnt5a regulators.
This has not been shown for other Wnts and, as Wnt5a may antag-
onize the effects ofthe Wnt1 pathway, it provides a mechanism for
integration of complex interactions of this family. As Wntl is
involved in cell to cell adhesion by increasing the level ofcatenins,
it is possible that Wnt5a counteracts the effect of Wntl by
decreasing cell adhesion, as recently published by (Torres et al,
1996), through affecting the interactions between cytoskeletal and
adhesion molecules. This is relevant to both normal tissue and
cancer, in which the Wnt5a pathway is up-regulated. It has
recently been shown that Wnt1 activates PKC (Cook et al, 1996)
and our results show that Wnt5a is up-regulated via PKC. These
data provide a mechanism for cross-talk between the two Wnt
classes and also a potential way for the antagonistic effects of the
two classes to be integrated.
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